Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
NPM1-ALK fusion
i
Other names:
Nucleophosmin (Nucleolar Phosphoprotein B23, Numatrin), Testicular Tissue Protein Li 128, Nucleolar Protein NO38, Numatrin, NPM1, Nucleophosmin 1, Nucleophosmin/Nucleoplasmin Family, Member 1, Nucleolar Phosphoprotein B23, NBLST3, CD246, Anaplastic Lymphoma Kinase, Anaplastic Lymphoma Kinase (Ki-1), CD246 Antigen, Mutant Anaplastic Lymphoma Kinase, ALK, ALK Receptor Tyrosine Kinase, Anaplastic Lymphoma Receptor Tyrosine Kinase, ALK Tyrosine Kinase Receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
238
;
4869
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
EML4-ALK variant 3 + TP53 mutation (5)
ALK fusion + ALK G1202R (4)
TP53 mutation + ALK positive (4)
ALK rearrangement + MET amplification (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
EML4-ALK fusion + ALK F1174L + ALK S1189C (3)
EML4-ALK fusion + ALK positive (3)
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L (3)
RANBP2-ALK rearrangement + TNFRSF8 expression (3)
ALK fusion + TP53 mutation (2)
ALK positive + ALK mutation (2)
ALK rearrangement + PD-L1 overepxression (2)
EML4-ALK + ALK G1202R + LIPI-NTRK1 (2)
EML4-ALK fusion + ALK G1202R (2)
EML4-ALK fusion + ALK rearrangement (2)
EML4-ALK fusion + TP53 mutation (2)
EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G (2)
MYC amplification + ALK F1174L (2)
MYCN amplification + ALK F1174V (2)
MYCN amplification + ALK rearrangement (2)
STRN-ALK fusion + MET amplification (2)
ALK exon 23 C1156Y missense mutation+ LOC101927285-ALK fusion (1)
ALK expression + RSRC1-ALK fusion (1)
ALK fusion + ALK G1269A (1)
ALK fusion + ALK I1179T (1)
ALK fusion + ALK V1180L (1)
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)
ALK fusion + EML4-ALK variant 3 + TP53 mutation (1)
ALK fusion + FAT3 mutation (1)
ALK fusion + FAT4 mutation (1)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK mutation + TMB-H (1)
ALK negative + S100A8 elevation (1)
ALK negative + S100A9 elevation (1)
ALK negative + SAA1 elevation (1)
ALK negative + SAA2 elevation (1)
ALK negative + TP53 deletion (1)
ALK positive + ALK G1202R (1)
ALK positive + ALK G1202R + ALK L1196M (1)
ALK positive + ALK L1196M + ALK D1203N (1)
ALK positive + DNMT3A N403Tfs* (1)
ALK positive + EML4-ALK fusion + TP53 mutation (1)
ALK positive + ERCC3 E259D + GNAS A436_P459del (1)
ALK positive + MYC amplification + CCND1 deletion (1)
ALK psoitive + ALK G1202R + ALK F1174C (1)
ALK rearrangement + ABCC11 overexpression (1)
ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)
ALK rearrangement + BRCA2 F2801fs (1)
ALK rearrangement + CDKN2A deletion (1)
ALK rearrangement + CDKN2B deletion (1)
ALK rearrangement + CTLA4 overexpression (1)
ALK rearrangement + EML4-ALK fusion + CCDC148-ALK fusion + PKDCC-ALK fusion + VIT-ALK fusion (1)
ALK rearrangement + MET amplification (1)
ALK wild-type + NT5E overexpression + PD-L1 expression (1)
ALK-EML4_V3a + PD-L1 overexpression (1)
ALK-EML4_V3b + PD-L1 overexpression (1)
BCL2L11 deletion + ALK positive (1)
CPE-ALK fusion + TP53 wild-type (1)
EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)
EGFR exon 19 deletion + STRN-ALK fusion (1)
EGFR mutation + ALK negative + TMB-H (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
EML4-ALK fusion + ALK I1171N (1)
EML4-ALK fusion + ALK I1171T (1)
EML4-ALK fusion + NFKBIA amplification + NKX2-1 amplification (1)
EML4-ALK fusion + TMB-L (1)
EML4-ALK fusion v1insLTBP1 (1)
IDH2 mutation + ALK fusion (1)
KIF5B-ALK fusion + ALK L1196M (1)
MET amplification + KLC1-ALK fusion (1)
MET exon 14 mutation + ALK wild-type (1)
MYCN amplification + ALK F1174L (1)
MYCN amplification + ALK R1275Q (1)
PIK3CA mutation + ALK fusion (1)
PIK3CA mutation + ALK positive (1)
PTEN mutation + ALK positive (1)
SLC8A1-PKDCC-ALK fusion + ALK overexpression (1)
SMARCA4 mutation + ALK positive (1)
STRN-ALK fusion + EML4-ALK fusion + EGFR T790M (1)
STRN-ALK fusion + KRAS G13D (1)
TMB-H + ALK rearrangement (1)
TPM3-NTRK1 fusion + ALK L1196M (1)
KMT2A rearrangement + NPM1 mutation (1)
PD-L1 underexpression + ALK wild-type (0)
EML4-ALK variant 3 + TP53 mutation (5)
ALK fusion + ALK G1202R (4)
TP53 mutation + ALK positive (4)
ALK rearrangement + MET amplification (3)
EGFR wild-type + ALK wild-type + PD-L1 expression (3)
EML4-ALK fusion + ALK F1174L + ALK S1189C (3)
EML4-ALK fusion + ALK positive (3)
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L (3)
RANBP2-ALK rearrangement + TNFRSF8 expression (3)
ALK fusion + TP53 mutation (2)
ALK positive + ALK mutation (2)
ALK rearrangement + PD-L1 overepxression (2)
EML4-ALK + ALK G1202R + LIPI-NTRK1 (2)
EML4-ALK fusion + ALK G1202R (2)
EML4-ALK fusion + ALK rearrangement (2)
EML4-ALK fusion + TP53 mutation (2)
EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G (2)
MYC amplification + ALK F1174L (2)
MYCN amplification + ALK F1174V (2)
MYCN amplification + ALK rearrangement (2)
STRN-ALK fusion + MET amplification (2)
ALK exon 23 C1156Y missense mutation+ LOC101927285-ALK fusion (1)
ALK expression + RSRC1-ALK fusion (1)
ALK fusion + ALK G1269A (1)
ALK fusion + ALK I1179T (1)
ALK fusion + ALK V1180L (1)
ALK fusion + EGFR exon 19 deletion + BRAF G466V + MAP2K1 F129L (1)
ALK fusion + EML4-ALK variant 3 + TP53 mutation (1)
ALK fusion + FAT3 mutation (1)
ALK fusion + FAT4 mutation (1)
ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion (1)
ALK mutation + TMB-H (1)
ALK negative + S100A8 elevation (1)
ALK negative + S100A9 elevation (1)
ALK negative + SAA1 elevation (1)
ALK negative + SAA2 elevation (1)
ALK negative + TP53 deletion (1)
ALK positive + ALK G1202R (1)
ALK positive + ALK G1202R + ALK L1196M (1)
ALK positive + ALK L1196M + ALK D1203N (1)
ALK positive + DNMT3A N403Tfs* (1)
ALK positive + EML4-ALK fusion + TP53 mutation (1)
ALK positive + ERCC3 E259D + GNAS A436_P459del (1)
ALK positive + MYC amplification + CCND1 deletion (1)
ALK psoitive + ALK G1202R + ALK F1174C (1)
ALK rearrangement + ABCC11 overexpression (1)
ALK rearrangement + ALK I1171N + ALK V1180L + BRCA2 F2801fs (1)
ALK rearrangement + BRCA2 F2801fs (1)
ALK rearrangement + CDKN2A deletion (1)
ALK rearrangement + CDKN2B deletion (1)
ALK rearrangement + CTLA4 overexpression (1)
ALK rearrangement + EML4-ALK fusion + CCDC148-ALK fusion + PKDCC-ALK fusion + VIT-ALK fusion (1)
ALK rearrangement + MET amplification (1)
ALK wild-type + NT5E overexpression + PD-L1 expression (1)
ALK-EML4_V3a + PD-L1 overexpression (1)
ALK-EML4_V3b + PD-L1 overexpression (1)
BCL2L11 deletion + ALK positive (1)
CPE-ALK fusion + TP53 wild-type (1)
EGFR T790M + STRN-ALK fusion + EGFR amplification + MET amplification (1)
EGFR exon 19 deletion + STRN-ALK fusion (1)
EGFR mutation + ALK negative + TMB-H (1)
EGFR negative + ALK negative + PD-L1 expression (1)
EGFR wild-type + ALK wild-type + NT5E overexpression + PD-L1 expression (1)
EML4-ALK fusion + ALK I1171N (1)
EML4-ALK fusion + ALK I1171T (1)
EML4-ALK fusion + NFKBIA amplification + NKX2-1 amplification (1)
EML4-ALK fusion + TMB-L (1)
EML4-ALK fusion v1insLTBP1 (1)
IDH2 mutation + ALK fusion (1)
KIF5B-ALK fusion + ALK L1196M (1)
MET amplification + KLC1-ALK fusion (1)
MET exon 14 mutation + ALK wild-type (1)
MYCN amplification + ALK F1174L (1)
MYCN amplification + ALK R1275Q (1)
PIK3CA mutation + ALK fusion (1)
PIK3CA mutation + ALK positive (1)
PTEN mutation + ALK positive (1)
SLC8A1-PKDCC-ALK fusion + ALK overexpression (1)
SMARCA4 mutation + ALK positive (1)
STRN-ALK fusion + EML4-ALK fusion + EGFR T790M (1)
STRN-ALK fusion + KRAS G13D (1)
TMB-H + ALK rearrangement (1)
TPM3-NTRK1 fusion + ALK L1196M (1)
KMT2A rearrangement + NPM1 mutation (1)
PD-L1 underexpression + ALK wild-type (0)
›
Associations
(4)
News
Trials
Search handles
@VivekSubbiah
Search handles
@VivekSubbiah
Filter by
Latest
almost3years
8/8 Tumors beyond ALK+ lymphomas such as histiocytic disorders, multiple myeloma, B-cell neoplasms, harbor ALK fusions. Ceritinib therapy documented durable complete response in an NPM1-ALK+ ALCL patient @OncoAlert @myESMO @ESMO_Open @montypal https://t.co/gaiUCSiT84 (@VivekSubbiah)
almost 3 years ago
Clinical
|
NPM1 (Nucleophosmin 1)
|
ALK fusion • NPM1-ALK fusion
|
Zykadia (ceritinib)
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login